China-based Centre Testing International Group Co., Ltd (CTI), a leading third-party testing and qualification services provider, has announced the 100% acquisition of compatriot firm Vectoring Pharmatech Ltd. This strategic move is designed to enhance CTI’s business layout in the pharmacy CMC (Chemistry, Manufacturing, and Controls) research field. No financial details of the acquisition were disclosed.
Business Expansion in Pharmacy CMC Research
The acquisition aims to strengthen CTI’s capabilities in key areas of pharmacy CMC research, including drug synthesis, drug prescription and production process development, quality research, stability research, and drug registration and application. This expansion will enable CTI to offer a more comprehensive suite of services to its clients, particularly in the pharmaceutical industry.
Vectoring Pharmatech: Background and Services
Vectoring Pharmatech, founded in 2016 by US returnees, specializes in providing professional drug research and development technical services. The company offers pre-clinical pharmacy study and testing, making it a valuable addition to CTI’s service portfolio. Vectoring Pharmatech’s expertise will complement CTI’s existing services, which include precise clinical testing, gene testing, functional medicine, pathological diagnosis, metabonomics, and scientific research services related to medical testing.-Fineline Info & Tech
